TGen (City of Hope) launched JAYseq™, a clinical whole-genome sequencing test tailored for multiple myeloma, designed to deliver comprehensive analysis in about three days. The test is positioned to streamline the genomic workup in myeloma by combining tumor analysis needs with faster turnaround for treatment-relevant findings. In conjunction with the launch, TGen described how JAYseq supports clinical decision-making by focusing on disease-specific genomic interrogation rather than general-purpose workflows. The move reflects a continuing industry push toward faster, more actionable sequencing pipelines that can be integrated into care at community oncology speed. For biotech and diagnostics vendors, rapid, disease-tailored turnaround is increasingly central to winning adoption—especially where serial genomic testing is needed to track resistance and guide next-line therapy selection.